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TITLE OF CASE  
 




We describe a 37 year old woman who presented with progressive deafness, 
visual loss and ataxia. She latterly developed neuropsychiatric problems, 
including cognitive impairment, paranoid delusions and episodes of altered 
consciousness. She was found to be heterozygous for the Q212P mutation in 
the prion protein gene. She died over a decade after initial presentation and a 




Prion diseases are a group of rare, invariably fatal, neurodegenerative conditions which 
can be acquired, inherited or arise sporadically. They are thought to occur due to 
misfolded forms of the prion protein which accumulate in the nervous system. Genetic 
prion disease accounts for about 10-15% of cases.[1] It results from mutations in the prion 
protein gene (PRNP) and has an autosomal dominant pattern of inheritance. Genetic prion 
diseases have historically been classified into three main subtypes based on 
clinicopathological features, namely genetic Creutzfeldt Jakob disease (CJD), fatal familial 
insomnia (FFI) and Gerstmann-Sträussler-Scheinker disease (GSS).[2] We describe an 
unusual presentation of genetic prion disease with clinical and neuropathological features 
most in keeping with GSS. 
 
CASE PRESENTATION  
 
A 37 year old, previously well, woman developed progressive deafness. This was 
followed, 2 years later, by painless, gradual, binocular visual loss. Clinical examination 
revealed bilateral optic atrophy, saccadic intrusion on pursuit eye movements and bilateral 
sensorineural hearing loss. Her reflexes were globally brisk and she had an ataxic gait. 
She had a history of polydactyly. Both of her parents were alive and in good health, as 
was her sister. Her elder sister died previously from a glioblastoma. Her grandmother died 




Initial blood tests were unremarkable, except for mildly positive anti-neutrophil cytoplasmic 
antibody against myeloperoxidase at 7 U/mL (normal 0-5 U/mL) and an elevated anti-
cardiolipin antibody at 23 U/mL (normal 1-10 U/mL). Serum angiotensin converting 
enzyme (ACE), syphilis serology and paraneoplastic antibody testing were either negative 
or normal. Visual evoked responses were delayed. Electroretinography and fluorescein 
angiography were normal. MRI brain with contrast was unremarkable with no white matter 
or inflammatory changes. CSF analysis was normal in cell count, protein, glucose and 
lactate levels. There were no oligoclonal bands detected. Initial genetic tests for ataxic and 
mitochondrial disorders were negative, as were tests for mutations commonly associated 
with hearing and vision loss (Table 1). A muscle biopsy showed no evidence of 
mitochondrial disease. While being investigated for breathlessness, she was found to 










Leber’s hereditary optic neuropathy 
m.1555 A>G & m.7445 A>G mutations (associated with deafness)  
TREATMENT  
 
In view of her positive immunology and despite the lack of inflammatory change on brain 
imaging and spinal fluid analysis, an immune mediated process was initially considered. 
Accordingly, steroids and other immunosuppressive agents were administered, but 
without meaningful response. She was also prescribed warfarin for a short time, which 
unfortunately resulted in a subdural haematoma requiring neurosurgical intervention.  
 
OUTCOME AND FOLLOW-UP   
 
Her condition continued to deteriorate and it became clear that she was suffering from a 
neurodegenerative process. At almost ten years since the onset of her symptoms, she 
now had severe ataxia, increased tone in all four limbs and very brisk reflexes. Her visual 
acuities were nil perception of light and she had bilateral cochlear implants. She also 
developed neuropsychiatric problems, including cognitive impairment, paranoid delusions 
and episodes of altered consciousness.  
 
Further genetic testing revealed that she was heterozygous for the Q212P mutation in the 
PRNP gene, raising the possibility of a genetic prion disease.  Serial brain imaging 
showed mild cerebellar atrophy (Figure 1). EEG revealed non-specific features only. CSF 
analysis for protein 14-3-3 was not performed. Her condition rapidly worsened over the 
following two years. She became severely disabled, requiring care in a nursing home, 
where she died aged 49 from aspiration pneumonia.  
 
Neuropathological examination demonstrated abnormal prion protein deposits confined to 
the cerebellar cortex and vermis (Figure 2), confirming the diagnosis of prion disease. The 
cerebellar cortex and dentate nucleus showed mild to moderate neuronal loss, astrocytic 





GSS was first described by three neuroscientists from a case they mutually treated in 
1936.[3] The original description was of a slowly progressive cerebellar ataxia, with later 
onset of cognitive decline. Since then, it has been associated with a range of different 
clinical features including parkinsonism, seizures, spastic paraparesis, amyotrophy, 
myoclonus, and dysarthria.[2] It has also been linked to numerous different mutations in 
the PRNP gene.[2]  
 
The case we describe was heterozygous for the Q212P mutation in the PRNP gene. This 
particular gene mutation has been described in two cases previously.[4,5] Young et al 
(1998) describe a 60 year old male who developed progressive incoordination, dysphagia 
and slurred speech.[4] He died 8 years after disease onset and was cognitively intact at 
the time of his death. He was heterozygous for the Q212P mutation. Beck et al (2010) 
describe a 36 year old female who presented with unsteadiness, worsening of 
handwriting, and slurred speech.[5] She had global ataxia, hypertonia and hyperreflexia. 
She latterly developed severe cognitive impairment. Somewhat unusually she was 
homozygous for the Q212P mutation, which is attributed to consanguinity within the 
family. 
 
Our case’s initial presentation with hearing and visual impairment is somewhat unusual. 
These features have been reported in GSS previously,[6,7,8,9] but they are not common 
and, to the best of our knowledge, they have not been observed in patients with the 
Q212P mutation. This might suggest that the occurrence of these symptoms in 
association with this mutation is merely coincidental in our case. Alternatively, it may just 
reflect the considerable phenotypic variability that exists within genetic prion diseases, 
even in families with the same PRNP gene mutation.[10,11] The reason for this clinical 
heterogeneity is not well understood. Its existence makes diagnosis of GSS difficult and 
can lead to patients being misdiagnosed with other conditions.[2]  
 
Diagnosis is also made more challenging by the fact that routine neurological 
investigations, including MRI, EEG and CSF analysis, tend to show non-specific features 
only and can be normal, even in advanced disease.[12] The possibility of a genetic prion 
disease is often only considered after identification of other family members with a similar 
disorder. However, as in our case, a positive family history is absent in a significant 
proportion of patients with genetic prion disease (12-88%, depending on the mutation).[2] 
Possible explanations for this include inaccurate family history data, death of family 
members prior to the development of disease, the occurrence of de novo mutations, or 
mutations with incomplete penetrance. Interestingly, Young et al (1998) mention an 
asymptomatic octogenarian sibling who is heterozygous for the Q212P mutation.[4] This 
would suggest that Q212P in its heterozygous state may have incomplete penetrance. 
The living family members of our case did not wish to undergo genetic testing. 
 
Early diagnosis of prion disease is important, not only because it allows patients and their 
families to access much needed counselling and support, but also because of the 
significant public health implications. This was particularly pertinent in our case because of 
the history of previous neurosurgery. Once diagnosed, our case was referred to the local 
infection control team so that contacts could be traced and measures put in place to 
minimise transmission risk in accordance with guidance from the Transmissible 
Spongiform Encephalopathy Subgroup of the Advisory Committee on Dangerous 
Pathogens.[13] It is important that family members are also informed of the potential to 
transmit disease via dental or surgical procedures.[14] 
 
The unusual presentation of a very rare condition, together with the absence of a positive 
family history, made diagnosis particularly challenging in this case. We hope that by 
highlighting these difficulties, others might learn from them. 
 
LEARNING POINTS/TAKE HOME MESSAGES  
 
• Genetic prion disease can be difficult to diagnose because of its clinical 
heterogeneity, rarity in everyday clinical practice, and lack of characteristic findings 
on routine neurological investigations. 
• The absence of a family history of neurodegenerative disease should not dissuade 
clinicians from considering the possibility of a genetic prion disease.  
• PRNP (prion protein gene) analysis should be considered routinely in all patients 
with unexplained ataxia or dementia. 
• Early diagnosis of prion disease is important because of its public health 
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FIGURE/VIDEO CAPTIONS figures should NOT be embedded in this document 
 
Figure 1. MRI brain scan showing mild cerebellar atrophy.  
 
Figure 2. (A) Abnormal prion protein deposits in the cerebellar cortex (12F10 
antibody 20x) with multicentric plaques, typical of GSS. (B) Abnormal prion 
protein deposits in the cerebellar vermis (12F10 antibody 10x).  
 
PATIENT’S PERSPECTIVE Optional but strongly encouraged – this has to be 
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